An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)

• ClinicalTrials.gov Identifier: NCT01811186
• Recruitment Status: Completed
• First Posted: March 14, 2013
• Results First Posted: March 10, 2017
• Last Update Posted: March 10, 2017
• Sponsor: Mundipharma Korea Ltd
• Information provided by (Responsible Party): Mundipharma Korea Ltd

Study Description

Brief Summary:

Objectives:

1. Objective of main interest

   - To assess the drop-out rate caused by adverse event* after 6 weeks treatment

2. Further objectives

   • To assess the drop-out rate caused by adverse event* after 1 week treatment
   • To assess the pain reduction rate after 6 weeks treatment from baseline
   • To assess the Euroquol (EQ-5D) quality of life
   • To assess physician's overall satisfaction
   • To assess subject's overall satisfaction
   • To assess safety

Condition or disease	Intervention/treatment	Phase
Chronic Pain	Drug: Oxycodone/naloxone	Phase 4

Detailed Description:

Study Design (Methodology):

This will be a single center, open-label, randomised, phase IV, exploratory interventional study to compare the efficacy and tolerability of current titration patterns and slow titration pattern with Targin® (Oxycodone/Naloxone) in the treatment of moderate to severe non-malignant chronic pain patients who are dissatisfied with their current analgesic medication World Health Organisation (WHO) step II analgesics).

Upon providing written informed consent, subject will be screened in the study and assessment will be performed at that time such as safety laboratory assessments, physical examination, vital sign, medical history taking, 24 hours pain intensity score. If the patient is eligible in inclusion/exclusion criteria at the time of visit 1, the patient will be randomized in a 1:1 ratio to allocate in Group A or Group B. Re-screening, study drug dose interruption is not allowed.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 261 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Supportive Care
• Official Title: An Interventional Study to Compare the Efficacy and Tolerability of Current and Slow Titration With Targin® in the Treatment of Moderate to Severe Non-malignant Chronic Pain (GLORY)
• Study Start Date: December 2012
• Actual Primary Completion Date: January 2014
• Actual Study Completion Date: June 2014

Arms and Interventions

Arm	Intervention/treatment
Group A; Start oxycodone/naloxone 10/5mg b.i.d. titration->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.	Drug: Oxycodone/naloxone; Oxycodone/naloxone titration; Other Name: Targin
Group B; Start oxycodone/naloxone 5/2.5mg b.i.d titration-> 10/5mg b.i.d.->20/10mg b.i.d.->30/15mg b.i.d->40/20mg b.i.d.	Drug: Oxycodone/naloxone; Oxycodone/naloxone titration; Other Name: Targin

Outcome Measures

Primary Outcome Measures :

1. Drop-out Rate Caused by Adverse Event After 6 Weeks Treatment [ Time Frame: 6 weeks ]
   To assess the drop-out rate caused by adverse event* after 6 weeks treatment

Secondary Outcome Measures :

1. The Drop-out Rate Due to an Adverse Event After 1 Week Treatment With the Study Drug. [ Time Frame: 1 week ]
   The drop-out rate due to an adverse event after treatment (1 week) by treatment arm were summarized and presented as frequency and percentage, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.
2. The Change of Pain Intensity Scores(NRS) From Baseline After 6 Weeks Treatment With the Study. [ Time Frame: 6 weeks ]
   Change in numeric rating scales (NRS) such as score for average pain levels over the previous 24 hours, from baseline to 6weeks. NRS score was measured from 0 (No pain) to 10(worst pain imaginable).
3. Change of Quality of Life (EQ-5D) Score After 6 Weeks Treatment With the Study Drug [ Time Frame: 6 weeks ]

   EQ-5D to measure of health related quality of life should be answered as one of 3 levels about current condition for 5 dimensions and was calculated total average by giving a weighting on 3 level of answers (EQ-5D levels into 'no problems' (level 1) and 'problems' (level 2 and 3)).

   Table of scores by each level for EQ-5D items: mobility(level 1=0, level2=0.069,level 3=0.314), self care(level 1=0, level2=0.104,level 3=0.214), usual activities(level 1=0, level2=0.036,level 3=0.094), pain/discomfort (level 1=0, level2=0.,level 3=0.386) and anxiety/depression(level 1=0, level2=0.071,level 3=0.2)

   *EQ-5D Total = 1 - 0.081 - (the score of the each level) - 0.269 (if at least one of level 3 presents)

   EQ-5D total score could be 0.919 in maximum and -0.594 in minimum if case all index indicates the level 3. So, if EQ-5D total score closed by "1" means that the healthy condition and high quality of life.

4. Assessment of Investigator's Overall Satisfaction After 6 Weeks Treatment With the Study Drug [ Time Frame: 6 weeks ]
   Investigator's overall satisfaction after treatment (6 weeks) (Clinical Global Impression of Change Scale(CGIC) 7 point scale) by treatment arm were summarized and presented as frequency and proportion, and the inter-group difference were compared by using a Chi-square test or Fisher's exact test.
5. Assessment of Subject's Overall Satisfaction After 6 Weeks Treatment With the Study Drug [ Time Frame: 6weeks ]
   At each visit, the subject assessed the overall satisfaction for efficacy by using the 7 point scale of Patient Global Impression of Change Scale(PGIC).

Eligibility Criteria

• Ages Eligible for Study: 20 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female ≥ 20 and <80 years of age
• Patients who have non-malignant chronic pain(≥90 days)
• Patients who have moderate to severe pain intensity which is not controlled with non-strong opioid
• Naïve patients for Oxycodone/Naloxone (Naïve patient defined as who did not treated for 90 days)
• Naïve patients for strong opioid (Naïve patient defined as who did not treated for 90 days)
• Patients who signed a written informed consent form

Exclusion Criteria:

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.
• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test
• Patients with known hypersensitivity to Oxycodone/Naloxone or to any of the excipients
• Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment
• Having used other investigational drugs at the time of enrollment, or within 30 days of enrollment

Contacts and Locations

Locations

Korea, Republic of

AMC

Seoul, Korea, Republic of

Sponsors and Collaborators

Mundipharma Korea Ltd

Investigators

• Principal Investigator: Hoseong Lee, Dr.; Asan Medical Center

More Information

• Responsible Party: Mundipharma Korea Ltd
• ClinicalTrials.gov Identifier: NCT01811186
• Other Study ID Numbers: OXN12-KR-403
• First Posted: March 14, 2013
• Results First Posted: March 10, 2017
• Last Update Posted: March 10, 2017
• Last Verified: January 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Mundipharma Korea Ltd:

moderate to severe non-malignant chronic pain

Additional relevant MeSH terms:

Chronic Pain; Pain; Neurologic Manifestations; Oxycodone; Naloxone; Analgesics, Opioid; Narcotics; Central Nervous System Depressants; Physiological Effects of Drugs; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Narcotic Antagonists